SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to reports of considering an all-cash bid for Warner Bros. Discovery, which the community is largely viewing as a bullish signal for avoiding dilution and indicating strong upcoming earnings. This comes amid an escalating takeover battle with Paramount, while many anticipate a pre-earnings rally or short squeeze ahead of its highly awaited report.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is a hot topic as investors analyze unaudited Q4 revenue and 2026 guidance for its multiple sclerosis treatment, Briumvi, ahead of an anticipated presentation at a major healthcare conference. The community is buzzing about Briumvi's strong market adoption and competitive advantages, further bolstered by recent issues impacting rival treatments. Despite operational strength, widespread discussion centers on the stock's valuation and the ongoing debate between its fundamental growth and market sentiment.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending amid a barrage of analyst downgrades, as concerns over a challenging AI technology transition and intensifying competition from rival creative software and AI tools fuel a heated debate among investors. While many view the stock as overvalued and vulnerable to disruption, a significant segment of the community sees the recent dip as a compelling buying opportunity, emphasizing Adobe's strong fundamentals and strategic AI integrations for long-term growth.

Memecoin on Injective taken over by the community.

Nonja

NONJA CRYPTO is trending as a high-leverage play on the Injective (INJ) ecosystem, which is gaining significant attention for its robust developer activity, strong revenue performance, and institutional interest, including staked ETF filings. The community is actively discussing NONJA's unique resilience, high burned liquidity, and dedicated base, positioning it for substantial upside as Injective's undervalued chain continues to grow.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery (WBD) is trending as it navigates an escalating takeover battle, with its board reportedly favoring Netflix's acquisition proposal over Paramount Skydance's (PSKY) all-cash offer, despite a personal financing guarantee. The community is buzzing with debate, weighing PSKY's perceived superior value and the potential for a significantly higher bid from either contender to secure market dominance in the evolving media landscape. Shareholders are closely watching for definitive developments in this strategic consolidation.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is experiencing significant volatility, primarily driven by continued discussions around executive share sales and recent concerns regarding new AI agent solutions entering the market. While some investors see market manipulation in the stock's rapid movements, many within the community view current levels as a compelling buying opportunity, emphasizing the company's robust balance sheet and its strategic position in the burgeoning agentic AI sector.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging amid positive financial outlook revisions and ongoing regulatory progress for its next-generation COVID and flu vaccines, complemented by funding for a pandemic flu trial. Community discussion centers on the company's perceived undervaluation and the long-term potential of its diverse mRNA pipeline, particularly in oncology, with many anticipating a substantial short squeeze. This renewed interest highlights a broader re-evaluation of Moderna's platform capabilities within the evolving biotech landscape.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics (CADL) is trending amid intense community speculation regarding an imminent major partnership or acquisition, with Novartis frequently mentioned as a potential suitor. This excitement is amplified by the upcoming J.P. Morgan Healthcare Conference, a hub for anticipated biopharma M&A, and recent FDA flexibility on CMC requirements, which could accelerate the BLA submission for its lead prostate cancer drug, CAN-2409. The community is actively debating the company's current low valuation against its promising clinical data, eagerly anticipating a transformative deal or further clarity on its expedited regulatory path.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is at the center of a contentious takeover bid for Warner Bros. Discovery, persistently pushing its all-cash offer while challenging Netflix's rival deal. The community is intensely debating WBD's repeated rejections, with many questioning if the board is prioritizing personal interests over shareholder value, especially as PSKY escalates with a lawsuit seeking financial transparency and plans to nominate new directors. This ongoing media M&A drama is further complicated by anticipated regulatory scrutiny for the alternative Netflix bid.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending due to its strong Q3 earnings report, which exceeded EPS expectations and included an optimistic FY26 revenue forecast, significantly driven by the accelerating adoption of its AI-powered Agentforce platform. This has ignited bullish sentiment among investors who see the stock as deeply undervalued and poised for a rebound. However, community discussion continues to reflect broader market skepticism about AI's impact on traditional software licensing models and the stock's past volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat Ratings...

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings...

Biomea Fusion (NASDAQ:BMEA) Price Target Cut to $6.00 by Analysts at Citigroup

Citigroup reduced their price objective on Biomea Fusion from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Monday...

Biomea Fusion FY2025 EPS Estimate Lowered by HC Wainwright

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - HC Wainwright lowered their FY2025 EPS estimates for Biomea Fusion in a research note issued on Wednesday, November 5th. HC Wainwright analyst J...

Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Moderate Buy" by Analysts

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, MarketBeat.com reports. One...

Biomea Fusion (NASDAQ:BMEA) Given New $12.00 Price Target at D. Boral Capital

D. Boral Capital dropped their price target on shares of Biomea Fusion from $16.00 to $12.00 and set a "buy" rating on the stock in a research note on Wednesday...

Shares of Biomea Fusion drew heightened attention from retail investors on Tuesday after the company disclosed a public offering of its common stock and warrants.&nbsp;The stock closed up 10.3% at $2.9 on Tuesday but dropped 24.8% to $2.18 in after-hours trading.The offer includes shares, pre-funded warrants in place of shares to certain investors and accompanying warrants for the purchase of shares.Biomea said it will also give the underwriters a 30-day option to buy up to 15% more shares and pre-funded warrants. Jefferies is the sole book running manager.The offering is being made under a shelf registration and is expected to close on or around June 20, subject to customary closing conditions.&nbsp;Biomea said the completion, size, and terms of the offering are subject to market conditions and are not guaranteed.The offering comes just days after Biomea Fusion reported updated data from its Phase I Covalent 103 trial of BMF-500 in relapsed or refractory acute leukemia.&nbsp;The study, presented at the European Hematology Association Congress, showed early signs of clinical benefit in heavily pretreated patients with FLT3 mutations.&nbsp;The company said it plans to conclude internal development of BMF-500 in oncology and is exploring strategic partnerships to advance the program.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.One user said the raise could bring in around $30 million and&nbsp;added that while the added dilution might pressure the stock short-term, the reduced risk could unlock further upside, predicting a return above $3 in the coming weeks.&nbsp;<stembedurl>https://stocktwits.com/hashbridges/message/618219066</stembedurl>Another user expressed disappointment at the timing of the offering, saying they anticipated it at a higher price and would now hold the stock through year-end.<stembedurl>https://stocktwits.com/aquira/message/618214880</stembedurl>The stock has declined 21.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

Biomea Fusion Slides After-Hours Following Stock-And-Warrant Offering; Retail Traders See Rebound Ahead

The offering follows early clinical data from Biomea’s BMF-500 leukemia program, which showed encouraging responses in heavily pretreated patients. 

Equity

Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know

Shares of Biomea Fusion attracted significant retail attention on Tuesday after H.C. Wainwright reduced its price target for the stock to $18 from $40, while maintaining a ‘Buy’ rating.&nbsp;The&nbsp;reduction followed the company’s first-quarter earnings report, where Biomea unveiled a strategic shift to focus on its core diabetes and obesity programs.&nbsp;As part of its strategy, Biomea has implemented a cost-reduction initiative, which includes a workforce reduction of nearly 35% to reduce overall operating expenses and extend its cash runway into Q4 2025.The firm also removed type 1 diabetes from its projections and pushed the launch of icovamenib for type 2 diabetes to 2031 from the previously anticipated 2029.Biomea’s stock price declined by 16.5%, closing at $1.67 on May 6, 2025. However, it rebounded slightly in after-hours trading, increasing by 1.74% to $1.70.Retail sentiment surged on Stocktwits, where sentiment was ‘bearish’ views amid a 1,400% uptick in message volume.&nbsp;The sentiment seemed to reflect speculation about the company’s next moves and the market’s potential reactions.One user questioned the company’s decision to delay share dilution when the stock was priced at $4 earlier this year, suggesting that the current price of $1.60 might not align with Biomea’s broader plans, hinting that something was amiss.&nbsp;<stembedurl>https://stocktwits.com/NGEA/message/613687181</stembedurl>Meanwhile, another user speculated that Biomea's recent actions could indicate a “short trap” and accumulation of shares ahead of potential positive news.&nbsp;The user pointed out that despite concerns of running out of cash, Biomea had not raised funds through share sales but instead reduced its workforce to stretch its runway.<stembedurl>https://stocktwits.com/NGEA/message/613678729</stembedurl>In its Q1 update, interim CEO Mick Hitchcock highlighted the company’s efforts to prioritize high-value opportunities, extend its cash runway, and maintain its focus on icovamenib and BMF-650.&nbsp;Biomea also reported a Q1 net loss of $29.3 million, with cash reserves of $36.2 million, expected to fund operations until Q4 2025.Shares of Biomea have fallen 54.7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Biomea Fusion's Stock Plummets After Price Target Cut — Bearish Retail Traders Speculate Next Moves

Biomea Fusion is realigning its focus on diabetes and obesity programs, cutting 35% of its workforce and consolidating operations to reduce costs. 

This account has been verified as an official BMEA representative.

Verified Account

Biomea Fusion IR

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

Biomea Fusion Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

BMEA
Biomea Fusion Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BMEA News

BMEABiomea Fusion Inc